YUMAB GmbH (“YUMAB”), a leading antibody discovery CRO headquartered in Braunschweig, Germany, and MOLCURE Inc. (“MOLCURE”), an AI-driven drug discovery company based in Kawasaki, Japan, announced their on-going collaboration now includes advancing the application of zero-shot AI technology for antibody discovery. The collaboration brings together complementary expertise and technologies. MOLCURE has a decade of experience in AI-design of antibodies and has accumulated over a billion proprietary experimental data points, and YUMAB has more than thirty years of technical excellence and research in antibody discovery, engineering and manufacturing. YUMAB and MOLCURE share a common vision to push the boundaries of antibody discovery for difficult to drug protein classes that are of […]
